Vatalanib
Description
Type: small molecule
Groups: investigational
Indication: Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).
Accession Number: DB04879 ( DB04879)
Description: Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.
Structure:
Prescription Products: Not Available
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
- No Brands
Brand Names
- No Brands
Brand Mixtures
Brand Name | Ingredients |
---|
Brand Name | Ingredients |
---|
Categories
- Antineoplastic Agents
- Protein Kinase Inhibitors
Pharmacology
Pharmacodynamics: Not Available
Mechanism of action: Vatalanib potently inhibits vascular endothelial growth factor (VEGF) receptor tyrosine kinases, important enzymes in the formation of new blood vessels that contribute to tumor growth and metastasis.
Absorption: Rapid onset of absorption
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half life: Approximately 6 hours.
Clearance: Not Available
Toxicity: Not Available
Affected organisms
- Not Available
SNP Mediated Adverse Drug Reactions
- Not Available
Pharmacoeconomics
- Not Available
Packagers:
- Not Available
Dosage forms
Form | Route | Strength |
---|
Form | Route | Strength |
---|
Prices
Unit description | Cost | Unit |
---|
Unit description | Cost | Unit |
---|
Patents
Country | Patent Number | Approved | Expires (estimated) |
---|
Interactions
Drug | Interaction |
---|
Drug | Interaction |
---|
Food Interactions:
- Not Available
Taxonomy
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
- Aminopyridazines
- Aryl chlorides
- Azacyclic compounds
- Chlorobenzenes
- Heteroaromatic compounds
- Hydrocarbon derivatives
- Imidolactams
- Organochlorides
- Pyridines and derivatives
- Secondary amines
substituent:
- Amine
- Aminopyridazine
- Aromatic heteropolycyclic compound
- Aryl chloride
- Aryl halide
- Azacycle
- Benzenoid
- Chlorobenzene
- Halobenzene
- Heteroaromatic compound
- Hydrocarbon derivative
- Imidolactam
- Monocyclic benzene moiety
- Organochloride
- Organohalogen compound
- Organonitrogen compound
- Phthalazine
- Pyridazine
- Pyridine
- Secondary amine
References
General Reference: # Yamamoto A, Watanabe H, Sueki H, Nakanishi T, Yasuhara H, Iijima M: Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity. J Dermatol. 2007 Jul;34(7):419-29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17584317 # Lijnen HR, Van Hoef B, Kemp D, Collen D: Inhibition of vascular endothelial growth factor receptor tyrosine kinases impairs adipose tissue development in mouse models of obesity. Biochim Biophys Acta. 2007 Sep;1770(9):1369-73. Epub 2007 Jun 15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17616257 # Jost LM, Gschwind HP, Jalava T, Wang Y, Guenther C, Souppart C, Rottmann A, Denner K, Waldmeier F, Gross G, Masson E, Laurent D: Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients. Drug Metab Dispos. 2006 Nov;34(11):1817-28. Epub 2006 Aug 1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16882767
External Links:
Resource | Link |
---|
Resource | Link |
---|
ATC Codes:
- Not Available
AHFS Codes:
- Not Available
MSDS: Download